Chi­nese deal­mak­ing: SARI nabs Italy’s NMS Group for $362M; In­ovio re­tools deal with Apol­lo­Bio

Two bio­phar­ma deals in­volv­ing Chi­nese com­pa­nies were an­nounced dur­ing the hol­i­days, mark­ing the be­gin­ning of what we ex­pect will be a boom­ing year for deal­mak­ing in Chi­na.

SARI nabs can­cer drug­mak­er in Italy for $362M

First, there was SARI, a Chi­nese biotech in­vest­ment com­pa­ny that just snatched 90% in­ter­ests in an Ital­ian on­col­o­gy com­pa­ny called NMS Group in a deal worth €300 mil­lion ($362 mil­lion). The deal was part eq­ui­ty in­jec­tion and part debt re­struc­tur­ing, and is ex­pect­ed to close some­time in Q1.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.